3 recruiting, 2 completed, 2 enrolling by invitation, 2 not yet recruiting. 2 Early Phase 1, 2 Phase 2, 1 Not applicable, 1 Phase 1, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Early Phase 1 | 2 | Not yet recruiting 1, Recruiting 1 |
| Phase 2 | 2 | Active not recruiting 1, Recruiting 1 |
| Not applicable | 1 | Unknown 1 |
| Phase 1 | 1 | Enrolling by invitation 1 |
| Phase 4 | 1 | Not yet recruiting 1 |
Follow UC - Ulcerative Colitis: new trials by email Literature Review of UC - Ulcerative Colitis trials Research Report on UC - Ulcerative Colitis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Oral Aeromonas sp. MTB Phage Therapy for Pouchitis in Patients With Ulcerative Colitis (UC) MTB-targeted phage therapy - Pouchitis, UC - Ulcerative Colitis | Early Phase 1 | Not yet recruiting | Jinling Hospital, China | 12 | 2027-01-01 | 2026-10-22 |
| Upadacitinib in Patients Hospitalized With Acute Severe Ulcerative Colitis Upadacitinib - UC - Ulcerative Colitis | Phase 4 | Not yet recruiting | University of California, San Francisco | 50 | 2026-10-15 | 2026-09-24 |
| ND-12 Combined With H-6 for Adult Chronic Inflammatory Diarrhea mesalazine, ND-12, ND-12/H-6 - Diarrhea Chronic, UC - Ulcerative Colitis | Early Phase 1 | Recruiting | The Second Hospital of Nanjing Medical University | 36 | 2026-07-20 | 2026-08-17 |
| To Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of LYNC-101 for Injection in Healthy Adult Participants LYNC-101, LYNC-101 Placebo - UC - Ulcerative Colitis | Phase 1 | Enrolling by invitation | LyncBio Therapeutics Co., Ltd. | 50 | 2026-05-28 | 2026-08-27 |
| Prophylactic Dexamethasone Before Infliximab in Moderate-to-Severe IBD Dexamethasone (IV) - Inflammatory Bowel Disease (IBD), CD - Crohn's Disease | Recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 300 | 2025-10-08 | 2026-02-03 | |
| ALPCO/Calprotectin CLIA Assay: Expected Values of Calprotectin in Healthy Subjects ALPCO Calprotectin CLIA - IBD (Inflammatory Bowel Disease), IBS - Irritable Bowel Syndrome | Completed | American Laboratory Products Company | 121 | 2025-07-07 | 2026-04-28 | |
| Safety and Efficacy of OD-07656 and of Subsequent Vedolizumab Therapy in Moderately to Severely Active Ulcerative Colitis OD-07656, Vedolizumab - Ulcerative Colitis (UC), UC - Ulcerative Colitis | Phase 2 | Recruiting | Odyssey Therapeutics, Inc. | 57 | 2025-06-02 | 2026-02-11 |
| A Phase 2 Study of D-2570 in Subjects With Moderately to Severely Active Ulcerative Colitis D-2570, Placebo - UC - Ulcerative Colitis, Moderately to Severely Active Ulcerative Colitis | Phase 2 | Active not recruiting | InventisBio Co., Ltd | 120 | 2025-05-22 | 2026-07-17 |
| Enabling Microbiomics- Driven Personalized Nutrition Inflammatory Bowel Disease (IBD), Irritable Bowel Syndrome (IBS) | Enrolling by invitation | Mayo Clinic | 4001 | 2025-03-28 | 2026-06-12 | |
| Impact of Therapeutic Intervention on Quality of Life in Patients With Ulcerative Colitis IBD-Inflammatory Bowel Disease, UC - Ulcerative Colitis | Completed | Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa | 234 | 2022-11-18 | 2025-12-02 | |
| Low FODMAP Diet on Nutritional Status, Disease Activity and Gut Microbiota in IBS and UC With Normal or Overweight BMI Low FODMAP diet, Standard diet - IBD - Inflammatory Bowel Disease, IBS - Irritable Bowel Syndrome | Not applicable | Unknown | Hospital General de Mexico | 105 | 2018-02-10 | 2019-10-29 |
Colitis, Ulcerative (11) · Inflammatory Bowel Diseases (6) · Crohn Disease (3) · Irritable Bowel Syndrome (3) · Celiac Disease (1) · Colitis, Microscopic (1) · Constipation (1) · Diarrhea (1) · Digestive System Diseases (1) · Pouchitis (1)
Colitis (11) · Colonic Diseases (11) · Gastroenteritis (11) · Gastrointestinal Diseases (11) · Intestinal Diseases (11) · Digestive System Diseases (10) · Inflammatory Bowel Diseases (5) · Colonic Diseases, Functional (3) · Enteritis (1) · Ileal Diseases (1) · Ileitis (1) · Malabsorption Syndromes (1) · Metabolic Diseases (1) · Nutritional and Metabolic Diseases (1) · Pathological Conditions, Signs and Symptoms (1)
Dexamethasone (1) · FODMAP Diet (1) · Injections (1) · Mesalamine (1) · upadacitinib (1) · vedolizumab (1)
American Laboratory Products Company (1) · Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (1) · Hospital General de Mexico (1) · InventisBio Co., Ltd (1) · Jinling Hospital, China (1) · LyncBio Therapeutics Co., Ltd. (1) · Mayo Clinic (1) · Odyssey Therapeutics, Inc. (1) · Second Affiliated Hospital, Zhejiang University, School of Medicine (1) · The Second Hospital of Nanjing Medical University (1) · University of California, San Francisco (1)
China (4) · United States (3) · Australia (2) · Austria (1) · Canada (1) · Czechia (1) · Jordan (1) · Lithuania (1) · Mexico (1) · Moldova (1) · New Zealand (1) · Poland (1) · Spain (1) · Ukraine (1)
Cexiong Fu (1) · Fangyu Wang (1) · Purna Kashyap, MBBS (1) · Sara Lewin, MD (1)
PMID 12851164, PMID 27496381, PMID 30243583, PMID 32801008, PMID 34115764, PMID 37302449, PMID 38582094, PMID 39708822, PMID 40461153